Literature DB >> 22579150

The psychiatric manifestations of mitochondrial disorders: a case and review of the literature.

Rebecca E Anglin1, Sarah L Garside, Mark A Tarnopolsky, Michael F Mazurek, Patricia I Rosebush.   

Abstract

OBJECTIVE: Mitochondrial disorders are caused by gene mutations in mitochondrial or nuclear DNA and affect energy-dependent organs such as the brain. Patients with psychiatric illness, particularly those with medical comorbidities, may have primary mitochondrial disorders. To date, this issue has received little attention in the literature, and mitochondrial disorders are likely underdiagnosed in psychiatric patients. DATA SOURCES: This article describes a patient who presented with borderline personality disorder and treatment-resistant depression and was ultimately diagnosed with mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes (MELAS) 3271. We also searched the literature for all case reports of patients with mitochondrial disorders who initially present with prominent psychiatric symptoms by using MEDLINE (from 1948-February 2011), Embase (from 1980-February 2011), PsycINFO (from 1806-February 2011), and the search terms mitochondrial disorder, mitochondria, psychiatry, mental disorders, major depression, anxiety, schizophrenia, and psychosis. STUDY SELECTION: Fifty cases of mitochondrial disorders with prominent psychiatric symptomatology were identified. DATA EXTRACTION: Information about the psychiatric presentation of the cases was extracted. This information was combined with our case, the most common psychiatric manifestations of mitochondrial disorders were identified, and the important diagnostic and treatment implications for patients with psychiatric illness were reviewed.
RESULTS: The most common psychiatric presentations in the cases of mitochondrial disorders included mood disorder, cognitive deterioration, psychosis, and anxiety. The most common diagnosis (52% of cases) was a MELAS mutation. Other genetic mitochondrial diagnoses included polymerase gamma mutations, Kearns-Sayre syndrome, mitochondrial DNA deletions, point mutations, twinkle mutations, and novel mutations.
CONCLUSIONS: Patients with mitochondrial disorders can present with primary psychiatric symptomatology, including mood disorder, cognitive impairment, psychosis, and anxiety. Psychiatrists need to be aware of the clinical features that are indicative of a mitochondrial disorder, investigate patients with suggestive presentations, and be knowledgeable about the treatment implications of the diagnosis. © Copyright 2012 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Year:  2012        PMID: 22579150     DOI: 10.4088/JCP.11r07237

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  40 in total

1.  NDUFV2 pseudogene (NDUFV2P1) contributes to mitochondrial complex I deficits in schizophrenia.

Authors:  Oded Bergman; Rachel Karry; Jumana Milhem; Dorit Ben-Shachar
Journal:  Mol Psychiatry       Date:  2018-12-10       Impact factor: 15.992

Review 2.  A mitochondrial bioenergetic basis of depression.

Authors:  N Jennifer Klinedinst; William T Regenold
Journal:  J Bioenerg Biomembr       Date:  2014-09-28       Impact factor: 2.945

3.  Brain cytochrome-c-oxidase as a marker of mitochondrial function: A pilot study in major depression using NIRS.

Authors:  Lisa Holper; Martin J Lan; Patrick J Brown; Elizabeth M Sublette; Ainsley Burke; John J Mann
Journal:  Depress Anxiety       Date:  2019-05-21       Impact factor: 6.505

4.  A new opportunity: metabolism and neuropsychiatric disorders.

Authors:  Tamas Kozicz; E Morava
Journal:  J Inherit Metab Dis       Date:  2018-07       Impact factor: 4.982

5.  Systems Analysis of the 22q11.2 Microdeletion Syndrome Converges on a Mitochondrial Interactome Necessary for Synapse Function and Behavior.

Authors:  Avanti Gokhale; Cortnie Hartwig; Amanda A H Freeman; Julia L Bassell; Stephanie A Zlatic; Christie Sapp Savas; Trishna Vadlamudi; Farida Abudulai; Tyler T Pham; Amanda Crocker; Erica Werner; Zhexing Wen; Gabriela M Repetto; Joseph A Gogos; Steven M Claypool; Jennifer K Forsyth; Carrie E Bearden; Jill Glausier; David A Lewis; Nicholas T Seyfried; Jennifer Q Kwong; Victor Faundez
Journal:  J Neurosci       Date:  2019-03-04       Impact factor: 6.167

6.  Psychotropic medications and mitochondrial toxicity.

Authors:  Rebecca Anglin; Patricia Rosebush; Michael Mazurek
Journal:  Nat Rev Neurosci       Date:  2012-07-25       Impact factor: 34.870

7.  The somatic common deletion in mitochondrial DNA is decreased in schizophrenia.

Authors:  Firoza Mamdani; Brandi Rollins; Ling Morgan; P Adolfo Sequeira; Marquis P Vawter
Journal:  Schizophr Res       Date:  2014-09-28       Impact factor: 4.939

8.  Mitochondria, Metabolism, and Redox Mechanisms in Psychiatric Disorders.

Authors:  Yeni Kim; Krishna C Vadodaria; Zsolt Lenkei; Tadafumi Kato; Fred H Gage; Maria C Marchetto; Renata Santos
Journal:  Antioxid Redox Signal       Date:  2019-02-01       Impact factor: 8.401

9.  Novel two-step derivation method for the synchronous analysis of inherited metabolic disorders using urine.

Authors:  Xiao-Qi Sheng; Yi-Chao Wang
Journal:  Exp Ther Med       Date:  2017-03-02       Impact factor: 2.447

10.  TOMM40 rs2075650 may represent a new candidate gene for vulnerability to major depressive disorder.

Authors:  Martyn McFarquhar; Rebecca Elliott; Shane McKie; Emma Thomas; Darragh Downey; Krisztina Mekli; Zoltan G Toth; Ian M Anderson; J F William Deakin; Gabriella Juhasz
Journal:  Neuropsychopharmacology       Date:  2014-01-29       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.